In this article, European Pharmaceutical Review’s Hannah Balfour explores some of big pharma’s latest developments in HIV treatment, with commentary from ViiV Healthcare’s Head of Research and Development, Kimberly Smith.
List view / Grid view
ViiV Healthcare is licencing Halozyme’s Enhanze® drug delivery technology to help develop ultra-long acting versions of its long-acting HIV pipeline products.
17 March 2016 | By Victoria White
The trial will study PEGPH20 in combination with nab-paclitaxel and gemcitabine in patients with tumours that accumulate high levels of hyaluronan...
31 July 2015 | By Victoria White
Eisai and Halozyme are to collaborate to evaluate Halaven in combination with PEGPH20 in first line HER2-negative metastatic breast cancer...